Hayati Demiraslan, Zeynep Ture, Aysegul Ulu Kılıc

The acute hepatic flare in a patient with chronic hepatitis C infection receiving pegylated interferon alpha 2b and ribavirin

Anahtar Kelimeler:

-

The acute hepatic flare in a patient with chronic hepatitis C infection receiving pegylated interferon alpha 2b and ribavirin

Hayati Demiraslan, Zeynep Ture, Aysegul Ulu Kılıc The pegylated interferon alpha and ribavirin treatment is well established therapy for hepatitis C virus (HCV) infection. During the treatment alanine aminotransferase (ALT) lare may be observed rarely. A 51-year-old female receiving pegylated interferon and ribavirin therapy for HCV infection, complained nausea, vomit- ing in seventh week of the therapy, and her ALT level was detected over 20 times above the normal level. Hepatitis B sur- face antigen, anti-nuclear antibody, anti-mitochondrial antibody, anti-double stranded DNA antibody and anti-hepatitis A virus IgM antibody were negative, and thyroid stimulating hormone was normal. HCV RNA level was 424 IU/ml. PEG IFN and ribavirin therapy was interrupted for three weeks, after liver enzyme level was detected less than 100U/L, the treatment was resumed. The patient was followed up for 2 months, ALT lare was not observed. In conclusion, we present a rare case with ALT lare, while receiving pegylated interferon and ribavirin therapy for chronic HCV infection.

Keywords:

-,

PDF

___

Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis c virus epidemiology in Europe, Canada and Israel. Liver Int 2011;31 Suppl 2:30-60.
Calvaruso V, Craxi A. 2011 European Association of The Study of The Liver Hepatitis C Virus Clinical Practice Guidelines. Liver Int 2012; 32 Suppl 1:2-8.
Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: An update. Hep- atology 2009; 49:1335-1374.
Amarapurkar DN. Flares on and off therapy during chronic hbv infection: Pathogenesis, significance and management. Hep B Annual 2008;5:12-22.
Demiraslan H, Aygen B, Yildiz O, Soyuer I, Gokahmetoglu S. Kronik hepatit C tedavisinde interferon-α 2a+ ribavirin ile peginterferon-α 2a ribavirin kombinasyonlarının karşılaştırıl- ması. Viral Hepatit Dergisi 2008;13:12-22.
Flink HJ, Sprengers D, Hansen BE, et al. Flares in chronic hepatitis b patients induced by the host or the virus? Re- lation to treatment response during peg-interferon alpha-2b therapy. Gut 2005;54:1604-1609.
Parana R, Schinoni MI, de Freitas LA, et al. Anti-golgi complex antibodies during pegylated-interferon therapy for hepatitis C. Liver Int 2006;26:1148-1154.
Yalcin K, Degertekin H, Yildiz F, Kilinc N. A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin. J Gastroenterol 2003;38:796-800.
Mishra P, DeVoss A, Pai R, Hart J, Jensen DM. Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2: A case report. Dig Dis Sci 2009; 54:1369-1372.